Related Experiment Video
Updated: Nov 24, 2025
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
09:34
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
3.6K
Alemtuzumab: A Review in Relapsing Remitting Multiple Sclerosis
1Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand. demail@springer.com.
Drugs
|December 28, 2020
Summary
Alemtuzumab effectively treats highly active relapsing-remitting multiple sclerosis (RRMS) by reducing relapses and disability. Long-term benefits are observed in about half of patients, with manageable safety concerns.
Area of Science:
- Neurology
- Immunology
- Pharmacology
Background:
- Alemtuzumab is an anti-CD52 monoclonal antibody approved for highly active relapsing-remitting multiple sclerosis (RRMS).
- Previous studies demonstrated its efficacy compared to interferon β-1a in reducing relapse rates and disability progression.
Purpose of the Study:
- To evaluate the long-term efficacy and safety of alemtuzumab in patients with highly active RRMS.
- To assess alemtuzumab's effectiveness in treatment-naïve and treatment-experienced patients.
Main Methods:
- Phase 3 clinical trials comparing intravenous alemtuzumab with subcutaneous interferon β-1a.
- Long-term follow-up of up to 9 years to assess treatment benefits and safety.
Main Results:
- Alemtuzumab significantly decreased relapse rates in both treatment-naïve and experienced patients.
- It also reduced disability progression in treatment-experienced patients.
- Approximately 50% of patients did not require retreatment, indicating sustained efficacy.
Conclusions:
- Alemtuzumab is an effective treatment for adults with highly active RRMS.
- It offers a favorable safety and tolerability profile, with manageable side effects.
- The convenient dosing regimen supports its role as a valuable therapeutic option.
